MAGEB3

Summary

MAGEB3 (MAGE family member B3, HGNC:6810) is a protein-coding gene on chromosome Xp21.2, encoding Melanoma-associated antigen B3 (O15480).

This gene is a MAGE-B subfamily member of the MAGE gene family. MAGE family member proteins direct the expression of tumor antigens recognized on a human melanoma by autologous cytolytic T lymphocytes. There are two known clusters of MAGE genes on chromosome X. The members of the MAGE-A subfamily are located in the Xq28 region, while the members of the MAGE-B subfamily are clustered in the Xp21 region.

Source: NCBI Gene 4114 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 40 total — 2 pathogenic
• MANE Select transcript: NM_002365

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6810
Approved symbol	MAGEB3
Name	MAGE family member B3
Location	Xp21.2
Locus type	gene with protein product
Status	Approved
Aliases	CT3.5
Ensembl gene	ENSG00000198798
Ensembl biotype	protein_coding
OMIM	300152
Entrez	4114

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000361644, ENST00000620842

RefSeq mRNA: 2 — MANE Select: NM_002365 NM_001386865, NM_002365

CCDS: CCDS14220

Canonical transcript exons

ENST00000361644 — 5 exons

Exon	Start	End
ENSE00001479447	30232827	30232916
ENSE00001479450	30230657	30230817
ENSE00001629891	30233262	30233363
ENSE00001739810	30231517	30231618
ENSE00002251740	30235864	30237495

Expression profiles

Bgee: expression breadth broad, 13 present calls, max score 76.04.

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.04	silver quality
right testis	UBERON:0004534	67.78	gold quality
left testis	UBERON:0004533	64.75	gold quality
testis	UBERON:0000473	64.59	gold quality
corpus epididymis	UBERON:0004359	64.55	gold quality
cauda epididymis	UBERON:0004360	57.22	silver quality
caput epididymis	UBERON:0004358	56.99	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	56.31	gold quality
lower lobe of lung	UBERON:0008949	54.44	silver quality
adult organism	UBERON:0007023	53.52	silver quality
pancreatic ductal cell	CL:0002079	52.32	silver quality
Brodmann (1909) area 46	UBERON:0006483	51.87	gold quality
buccal mucosa cell	CL:0002336	50.96	gold quality
epithelial cell of pancreas	CL:0000083	49.87	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
hair follicle	UBERON:0002073	49.18	gold quality
quadriceps femoris	UBERON:0001377	49.14	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
thymus	UBERON:0002370	48.90	gold quality
choroid plexus epithelium	UBERON:0003911	48.89	gold quality
myocardium	UBERON:0002349	48.87	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
oviduct epithelium	UBERON:0004804	48.81	gold quality
vastus lateralis	UBERON:0001379	48.80	gold quality
cardiac muscle of right atrium	UBERON:0003379	48.55	gold quality
CA1 field of hippocampus	UBERON:0003881	48.50	gold quality
left ventricle myocardium	UBERON:0006566	48.24	gold quality
orbitofrontal cortex	UBERON:0004167	48.20	gold quality
upper arm skin	UBERON:0004263	48.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.78

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

24 targeting MAGEB3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-4735-5P	99.43	68.49	1780
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-6830-5P	99.01	68.73	1884
HSA-MIR-138-2-3P	98.91	68.33	1643
HSA-MIR-4773	98.35	67.30	1710
HSA-MIR-561-5P	98.25	68.13	1365
HSA-MIR-12120	98.05	68.44	1768
HSA-MIR-483-3P	97.77	64.95	731
HSA-MIR-4678	97.59	68.31	902
HSA-MIR-5699-5P	97.36	67.03	1014
HSA-MIR-584-5P	95.82	68.05	848

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ndnl2	ENSDARG00000058212
rattus_norvegicus	Mageb3	ENSRNOG00000038269
drosophila_melanogaster	MAGE	FBGN0037481

Paralogs (37): MAGEC2 (ENSG00000046774), TRO (ENSG00000067445), MAGEB2 (ENSG00000099399), MAGED2 (ENSG00000102316), MAGEB4 (ENSG00000120289), MAGEA9 (ENSG00000123584), MAGEA10 (ENSG00000124260), MAGEA4 (ENSG00000147381), MAGED4 (ENSG00000154545), MAGEC1 (ENSG00000155495), MAGEA8 (ENSG00000156009), MAGEC3 (ENSG00000165509), MAGEB6 (ENSG00000176746), MAGEB18 (ENSG00000176774), MAGEF1 (ENSG00000177383), MAGEB10 (ENSG00000177689), MAGED1 (ENSG00000179222), NDN (ENSG00000182636), MAGEB17 (ENSG00000182798), MAGEA2B (ENSG00000183305), NSMCE3 (ENSG00000185115), MAGEA11 (ENSG00000185247), MAGEE2 (ENSG00000186675), MAGED4B (ENSG00000187243), MAGEH1 (ENSG00000187601), MAGEB5 (ENSG00000188408), MAGEB16 (ENSG00000189023), MAGEA6 (ENSG00000197172), MAGEA1 (ENSG00000198681), MAGEE1 (ENSG00000198934), MAGEA12 (ENSG00000213401), MAGEB1 (ENSG00000214107), MAGEA3 (ENSG00000221867), MAGEB6B (ENSG00000232030), MAGEL2 (ENSG00000254585), MAGEA9B (ENSG00000267978), MAGEA2 (ENSG00000268606)

Protein

Protein identifiers

Melanoma-associated antigen B3 — O15480 (reviewed: O15480)

Alternative names: MAGE-B3 antigen

All UniProt accessions (1): O15480

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Expressed in testis.

RefSeq proteins (2): NP_001373794, NP_002356* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002190	MHD_dom	Domain
IPR021072	MAGE_N	Domain
IPR037445	MAGE	Family
IPR041898	MAGE_WH1	Homologous_superfamily
IPR041899	MAGE_WH2	Homologous_superfamily

Pfam: PF01454, PF12440

UniProt features (6 total): sequence variant 2, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15480-F1	75.34	0.54

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 34 (showing top): ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, chrXp21, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_DN, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, DCA_UP.V1_DN, KRAS.PROSTATE_UP.V1_UP, MIR548E_5P, MIR1250_3P, MIR6835_3P, MIR4773, MIR12120, MIR4735_5P, MIR5699_5P, GSE13411_NAIVE_VS_SWITCHED_MEMORY_BCELL_UP

GO Biological Process (1): negative regulation of transcription by RNA polymerase II (GO:0000122)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

194 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAGEB3	BCLAF3	A2AJT9	512
MAGEB3	NR0B1	P51843	461
MAGEB3	ANKRD45	Q5TZF3	422
MAGEB3	KIAA1210	Q9ULL0	418
MAGEB3	ZNF518A	Q6AHZ1	390
MAGEB3	FTHL17	Q9BXU8	331
MAGEB3	IL1RAPL1	Q9NZN1	330
MAGEB3	GAR1	Q9NY12	321
MAGEB3	ZNF135	P52742	317
MAGEB3	LUZP4	Q9P127	305
MAGEB3	TASL	Q9HAI6	302
MAGEB3	EBPL	Q9BY08	300
MAGEB3	CELF5	Q8N6W0	287
MAGEB3	ZC4H2	Q9NQZ6	272
MAGEB3	GAGE4	P0DSO3	271

IntAct

10 interactions, top by confidence:

A	B	Type	Score
MAGEB3	PPP1R7	psi-mi:“MI:0915”(physical association)	0.560
MAGEB3	JPH3	psi-mi:“MI:0915”(physical association)	0.560
MAGEB3	PPP1R7	psi-mi:“MI:0914”(association)	0.560
MAGEA1	MAGEB3	psi-mi:“MI:0914”(association)	0.530
MAGEA1	ANKHD1	psi-mi:“MI:0914”(association)	0.350
MAGEB3	MYH7B	psi-mi:“MI:0914”(association)	0.350

BioGRID (8): MAGEB3 (Affinity Capture-MS), PPP1R7 (Affinity Capture-MS), MAGEB3 (Affinity Capture-MS), PPP1R7 (Affinity Capture-MS), CD200R1 (Affinity Capture-MS), PPP1R7 (Affinity Capture-MS), MAGEB3 (Affinity Capture-MS), CHERP (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A8MXT2, B2KFW1, O15479, O15480, O15481, O15553, P0C6Y7, P10073, P17040, P25233, P43355, P43356, P43357, P43358, P43360, P43362, P43363, P43364, P43366, Q13342, Q16666, Q4R998, Q5PPP4, Q5RD14, Q6AY37, Q6PCZ4, Q8BQR7, Q8IWY8, Q8IX06, Q8N660, Q8N7X4, Q8TD90, Q96DU7, Q96LZ2, Q96M61, Q99608

Diamond homologs: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A6NCF6, A6QLI5, A8MXT2, O15479, O15480, O15481, O60732, P25233, P43355, P43356, P43357, P43358, P43360, P43361, P43362, P43363, P43364, P43365, P43366, Q12816, Q4R998, Q5PPP4, Q5RFC2, Q6AY37, Q6ITT4, Q6PCZ4, Q8BQR7, Q8N7X4, Q8TD90, Q8TD91, Q96JG8, Q96LZ2, Q96M61, Q96MG7, Q99608, Q9BE18

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	32
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2424934	NC_000023.10:g.(?28807451)(31241248_?)del	Pathogenic
564805	GRCh37/hg19 Xp22.11-21.1(chrX:24650157-31844543)x2	Pathogenic

SpliceAI

476 predictions. Top by Δscore:

Variant	Effect	Δscore
X:30230818:G:GG	donor_gain	0.9900
X:30235858:CTCCA:C	acceptor_loss	0.9900
X:30235859:TCCA:T	acceptor_loss	0.9900
X:30235860:CCAGG:C	acceptor_loss	0.9900
X:30235861:CA:C	acceptor_loss	0.9900
X:30235862:A:AG	acceptor_gain	0.9900
X:30235862:A:C	acceptor_loss	0.9900
X:30235862:AG:A	acceptor_gain	0.9900
X:30235862:AGGT:A	acceptor_gain	0.9900
X:30235863:G:GA	acceptor_gain	0.9900
X:30235863:GG:G	acceptor_gain	0.9900
X:30235863:GGT:G	acceptor_gain	0.9900
X:30235863:GGTG:G	acceptor_gain	0.9900
X:30235863:GGTGC:G	acceptor_gain	0.9900
X:30230816:GA:G	donor_gain	0.9800
X:30230805:G:GG	donor_gain	0.9700
X:30230810:GTTCT:G	donor_gain	0.9700
X:30230811:TTCTT:T	donor_gain	0.9700
X:30230800:GCGAA:G	donor_gain	0.9400
X:30230802:G:GT	donor_gain	0.9400
X:30232825:A:G	acceptor_gain	0.9400
X:30232826:GGCA:G	acceptor_gain	0.9400
X:30230812:TCTTG:T	donor_gain	0.9300
X:30230814:TTGA:T	donor_gain	0.9100
X:30230815:TGA:T	donor_gain	0.9100
X:30230816:GAG:G	donor_gain	0.9100
X:30232915:AG:A	donor_loss	0.9000
X:30232916:GG:G	donor_loss	0.9000
X:30232917:GTGA:G	donor_loss	0.9000
X:30232918:TGAGC:T	donor_loss	0.9000

AlphaMissense

2310 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:30236747:T:A	W275R	0.970
X:30236747:T:C	W275R	0.970
X:30236795:T:C	F291L	0.961
X:30236797:T:A	F291L	0.961
X:30236797:T:G	F291L	0.961
X:30236742:T:C	F273S	0.960
X:30236750:G:C	G276R	0.960
X:30236645:T:C	F241L	0.959
X:30236647:T:A	F241L	0.959
X:30236647:T:G	F241L	0.959
X:30236414:T:C	F164L	0.955
X:30236416:T:A	F164L	0.955
X:30236416:T:G	F164L	0.955
X:30236600:T:C	F226L	0.953
X:30236602:C:A	F226L	0.953
X:30236602:C:G	F226L	0.953
X:30236779:G:C	K285N	0.953
X:30236779:G:T	K285N	0.953
X:30236749:G:C	W275C	0.943
X:30236749:G:T	W275C	0.943
X:30236741:T:C	F273L	0.938
X:30236743:C:A	F273L	0.938
X:30236743:C:G	F273L	0.938
X:30236801:G:C	A293P	0.934
X:30236694:A:C	Y257S	0.925
X:30236697:T:C	L258P	0.925
X:30236751:G:A	G276D	0.915
X:30236706:G:C	R261P	0.914
X:30236693:T:C	Y257H	0.911
X:30236638:C:A	H238Q	0.910

dbSNP variants (sampled 300 via entrez): RS1000534614 (X:30234211 G>A), RS1001404124 (X:30235758 A>C,T), RS1002125262 (X:30236153 G>T), RS1002431738 (X:30230033 G>A), RS1003256405 (X:30231960 C>A), RS1003699400 (X:30232969 C>A), RS1004122809 (X:30237582 C>T), RS1004152502 (X:30237308 A>T), RS1004153623 (X:30232467 A>C), RS1005769779 (X:30232387 G>A), RS1006063419 (X:30234948 C>G), RS1006114444 (X:30234451 C>T), RS1007469543 (X:30233805 G>A), RS1007497620 (X:30230737 C>T), RS1007780972 (X:30237040 T>C)

Disease associations

OMIM: gene MIM:300152 | disease phenotypes: MIM:310200

GenCC curated gene-disease

Mondo (1): Duchenne muscular dystrophy (MONDO:0010679)

Orphanet (1): Duchenne muscular dystrophy (Orphanet:98896)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D020388	Muscular Dystrophy, Duchenne	C05.651.534.500.300; C10.668.491.175.500.300; C16.320.322.562; C16.320.577.300

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
CGP 52608	affects binding, increases reaction	1
licochalcone B	increases expression	1
Benzo(a)pyrene	affects methylation	1
Tretinoin	increases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00819845	PHASE4	UNKNOWN	Ramipril Versus Carvedilol in Duchenne and Becker Patients
NCT01422200	PHASE4	COMPLETED	Flu Vaccine Study in Neuromuscular Patients 2011
NCT01999075	PHASE4	COMPLETED	Stacking Exercises Aid the Decline in FVC and Sick Time
NCT04687020	PHASE4	ACTIVE_NOT_RECRUITING	Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
NCT04708314	PHASE4	TERMINATED	An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy
NCT05412394	PHASE4	RECRUITING	Once Weekly Infant Corticosteroid Trial for DMD
NCT06713135	PHASE4	ACTIVE_NOT_RECRUITING	A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
NCT07542314	PHASE4	NOT_YET_RECRUITING	Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
NCT00004646	PHASE3	COMPLETED	Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy
NCT00110669	PHASE3	COMPLETED	High-dose Prednisone in Duchenne Muscular Dystrophy
NCT00308113	PHASE3	TERMINATED	CoQ10 and Prednisone in Non-Ambulatory DMD
NCT00839033	PHASE3	TERMINATED	Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders
NCT01247207	PHASE3	COMPLETED	Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
NCT01557400	PHASE3	COMPLETED	Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
NCT01603407	PHASE3	COMPLETED	Finding the Optimum Regimen for Duchenne Muscular Dystrophy
NCT01648634	PHASE3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02255552	PHASE3	COMPLETED	Study of Eteplirsen in DMD Patients
NCT02354352	PHASE3	COMPLETED	Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
NCT02500381	PHASE3	COMPLETED	Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT02814019	PHASE3	TERMINATED	A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
NCT02851797	PHASE3	COMPLETED	Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
NCT03354039	PHASE3	COMPLETED	Tamoxifen in Duchenne Muscular Dystrophy
NCT03532542	PHASE3	TERMINATED	An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
NCT03603288	PHASE3	TERMINATED	Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)
NCT03642145	PHASE3	WITHDRAWN	A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT03917719	PHASE3	TERMINATED	An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
NCT04060199	PHASE3	COMPLETED	Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
NCT04281485	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT04371666	PHASE3	TERMINATED	Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
NCT04587908	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）
NCT04632940	PHASE3	TERMINATED	Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
NCT04768062	PHASE3	UNKNOWN	Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
NCT05096221	PHASE3	COMPLETED	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05689164	PHASE3	TERMINATED	A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
NCT05881408	PHASE3	ACTIVE_NOT_RECRUITING	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05933057	PHASE3	RECRUITING	Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05967351	PHASE3	ENROLLING_BY_INVITATION	A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
NCT07160634	PHASE3	RECRUITING	A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT07587242	PHASE3	NOT_YET_RECRUITING	A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping